Katharina Elisabeth Blankart : Citation Profile


Are you Katharina Elisabeth Blankart?

Universität Duisburg-Essen (95% share)
Universität Hamburg (5% share)

3

H index

0

i10 index

20

Citations

RESEARCH PRODUCTION:

9

Articles

RESEARCH ACTIVITY:

   7 years (2011 - 2018). See details.
   Cites by year: 2
   Journals where Katharina Elisabeth Blankart has often published
   Relations with other researchers
   Recent citing documents: 6.    Total self citations: 6 (23.08 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pfi221
   Updated: 2020-11-21    RAS profile: 2020-09-09    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Stargardt, Tom (3)

Authors registered in RePEc who have co-authored more than one work in the last five years with Katharina Elisabeth Blankart.

Is cited by:

Lancsar, Emily (2)

Gu, Yuanyuan (2)

Leidl, Reiner (1)

Fernandez, Jose Luis (1)

Hu, Min (1)

Cites to:

Devlin, Nancy (9)

Stargardt, Tom (8)

Schreyögg, Jonas (6)

Parkin, David (6)

Leidl, Reiner (5)

Anell, Anders (3)

Costa-Font, Joan (2)

Docteur, Elizabeth (2)

Fernandez, Jose Luis (2)

Vandoros, Sotiris (2)

Claxton, Karl (2)

Main data


Where Katharina Elisabeth Blankart has published?


Journals with more than one article published# docs
Health Policy6
The European Journal of Health Economics3

Recent works citing Katharina Elisabeth Blankart (2020 and 2019)


YearTitle of citing document
2019Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. (2019). Kanavos, Panos ; Tinelli, Michela ; Visintin, Erica. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:118-129.

Full description at Econpapers || Download paper

2019What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. (2019). Cairns, John ; Maynou, Laia. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:130-139.

Full description at Econpapers || Download paper

2019Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland. (2019). Sevgur, Serperi ; Gambold, Liesl ; Zieliska, Dorota Anna ; Wranik, Wiesawa Dominika. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:191-202.

Full description at Econpapers || Download paper

2020Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. (2020). Kanavos, Panos ; Mills, Mackenzie. In: Health Policy. RePEc:eee:hepoli:v:124:y:2020:i:3:p:239-251.

Full description at Econpapers || Download paper

2020Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands. (2020). , Paul ; Vermeulen, Karin M ; Nicolet, Anna. In: PLOS ONE. RePEc:plo:pone00:0235666.

Full description at Econpapers || Download paper

2019Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree. (2019). Herpers, M ; Ruof, J ; Worm, F ; Dintsios, C M. In: Health Economics Review. RePEc:spr:hecrev:v:9:y:2019:i:1:d:10.1186_s13561-019-0254-6.

Full description at Econpapers || Download paper

Works by Katharina Elisabeth Blankart:


YearTitleTypeCited
2011A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention In: Health Policy.
[Full Text][Citation analysis]
article0
2012A systematic review of coverage decision-making on health technologies—Evidence from the real world In: Health Policy.
[Full Text][Citation analysis]
article8
2013Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis In: Health Policy.
[Full Text][Citation analysis]
article3
2016Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia In: Health Policy.
[Full Text][Citation analysis]
article6
2016Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark In: Health Policy.
[Full Text][Citation analysis]
article0
2016Dispensing behaviour of pharmacies in prescription drug markets In: Health Policy.
[Full Text][Citation analysis]
article0
2014Analysing coverage decision-making: opening Pandora’s box? In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2016The diffusion of generics after patent expiry in Germany In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2018The impact of physician-level drug budgets on prescribing behavior In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated November, 2 2020. Contact: CitEc Team